PMID- 21707704
OWN - NLM
STAT- MEDLINE
DCOM- 20111019
LR  - 20220519
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 58
IP  - 7
DP  - 2011 Jun
TI  - Relevance of cohort design for studying the frequency of the ERG rearrangement in 
      prostate cancer.
PG  - 1028-36
LID - 10.1111/j.1365-2559.2011.03862.x [doi]
AB  - AIMS: ERG rearrangements, mostly resulting in TMPRSS2-ERG fusions, are frequent 
      alterations in prostate cancer (PCa), with a frequency ranging from 15% to 78%. 
      As the reason for this variability is unknown, our aim was to investigate the ERG 
      rearrangement frequency with a cohort design. METHODS AND RESULTS: We assessed 
      three well-defined cohorts for ERG rearrangements, using fluorescence in situ 
      hybridization (FISH). The first cohort comprised 119 prostatectomy specimens. The 
      second and third cohorts included incidentally diagnosed PCa [71 
      cystoprostatectomy specimens, and 105 transurethral resection of the prostate 
      (TURP) specimens]. Seventy of 119 (59%) cases of the prostatectomy cohort 
      harboured ERG rearrangements. Regarding zonal origin, 2/11 (18%) transition zone 
      (TZ) foci and 75/145 (52%) peripheral zone (PZ) foci harboured ERG 
      rearrangements. Within the cystoprostatectomies, 24/71 (34%) cases harboured ERG 
      rearrangements. Regarding zonal origin, 2/9 (22%) TZ foci and 26/86 (30%) PZ foci 
      harboured ERG rearrangements. PCa incidentally identified by TURP harboured ERG 
      rearrangements in 31/105 (29%) cases. CONCLUSIONS: ERG rearrangements occur in TZ 
      PCa, although at a lower frequency than in PZ PCa. We confirmed that 
      approximately half of all prostatectomies harbour ERG rearrangements. However, 
      the frequency in incidentally diagnosed PCa cohorts was significantly lower, even 
      if multifocality was considered. Consequently, zonal origin and cohort design are 
      key for studying the clinical implications of ERG rearrangements.
CI  - (c) 2011 Blackwell Publishing Limited.
FAU - Braun, Martin
AU  - Braun M
AD  - Institute of Pathology, Comprehensive Cancer Centre, University Hospital of 
      Tuebingen, Tuebingen, Germany.
FAU - Scheble, Veit J
AU  - Scheble VJ
FAU - Menon, Roopika
AU  - Menon R
FAU - Scharf, Gregor
AU  - Scharf G
FAU - Wilbertz, Theresia
AU  - Wilbertz T
FAU - Petersen, Karen
AU  - Petersen K
FAU - Beschorner, Christine
AU  - Beschorner C
FAU - Reischl, Markus
AU  - Reischl M
FAU - Kuefer, Rainer
AU  - Kuefer R
FAU - Schilling, David
AU  - Schilling D
FAU - Stenzl, Arnulf
AU  - Stenzl A
FAU - Kristiansen, Glen
AU  - Kristiansen G
FAU - Rubin, Mark A
AU  - Rubin MA
FAU - Fend, Falko
AU  - Fend F
FAU - Perner, Sven
AU  - Perner S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (ERG protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TMPRSS2-ERG fusion protein, human)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcriptional Regulator ERG)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.- (TMPRSS2 protein, human)
SB  - IM
MH  - Adenocarcinoma/*genetics/pathology
MH  - Cohort Studies
MH  - Gene Fusion
MH  - *Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Oncogene Proteins, Fusion/genetics
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*genetics/pathology
MH  - Research Design
MH  - Serine Endopeptidases/genetics
MH  - Trans-Activators/*genetics
MH  - Transcriptional Regulator ERG
EDAT- 2011/06/29 06:00
MHDA- 2011/10/20 06:00
CRDT- 2011/06/29 06:00
PHST- 2011/06/29 06:00 [entrez]
PHST- 2011/06/29 06:00 [pubmed]
PHST- 2011/10/20 06:00 [medline]
AID - 10.1111/j.1365-2559.2011.03862.x [doi]
PST - ppublish
SO  - Histopathology. 2011 Jun;58(7):1028-36. doi: 10.1111/j.1365-2559.2011.03862.x.